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Introduction

Endometrial cancer (EC) is the most common gynecologic malignancy in the United
States (U.S.) annually affecting >50,000 patients in the U.S. and >380,000 patients worldwide
with increasing incidence and prevalence. Although most women are diagnosed with earlystage disease following surgical staging, approximately 10-15% have nodal involvement at
diagnosis [1, 2]. The primary lymphatic drainage of the uterus is to the pelvic lymph nodes,
although the fundus can directly drain to the para-aortic lymph nodes (PALN) [3].

Women with advanced stage EC with pelvic and PALN involvement are commonly
managed with a combination of adjuvant chemotherapy and/or external beam radiation
therapy (EBRT) to areas of initial disease involvement with or without vaginal brachytherapy (BT)
after surgical staging [4]. In a phase 3 randomized trial Postoperative Radition Therapy for
Endometrial Carcinoma (PORTEC-3), patients with high-risk EC including stage IA grade 3 with
lymphovascular space invasion, stage IB grade 3, stage IIIA, IIIB, IIIC, and stage IA-III with serous
and clear cell histology were randomized to either adjuvant chemoradiation versus radiation
therapy (RT) only. The updated analysis of the PORTEC-3 showed significantly improved overall
survival and failure-free survival with chemoradiation with largest failure-free survival benefit
observed in women with stage III disease [5, 6]. Furthermore, the large randomized phase III
trial Gynecologic Oncology Group (GOG-258) reported that chemoradiotherapy was associated
with a lower 5-year vaginal (2% vs. 7%), pelvic and para-aortic (11% vs. 20%) lymph node
recurrence than chemotherapy alone [7].

PALN involvement occurs in only about 7-8% of EC overall; however, when pelvic lymph
nodes are positive for carcinoma, the risk of PALN involvement rises to 50-60% [8]. While the
importance of PALN metastases as a predictor of poor patient outcome has been recognized
and appropriately reflected in the International Federation of Obstetrics and Gynecology (FIGO)
staging with 2 different categories of stage IIIC based on the absence (IIIC1) or the presence
(IIIC2) of the PALN involvement [8, 9], the role and extent of PALN dissection in the surgical
staging of EC has not been thoroughly defined [10, 11]. Although current guidelines
recommend PALN dissection for selective high-risk patients [12], PALN sampling is commonly
performed to avoid the morbidity of the full lymphadenectomy in the absence of prospective
randomized trials showing clear therapeutic value of para-aortic lymphadenectomy [13]. In the
Determining the Sensitivity of Sentinel Lymph Nodes Identified with Robotic Fluorescence
Imaging (FIRES) multicenter prospective cohort study, sentinel lymph node biopsy has been
shown as a safe replacement of lymphadenectomy with a 97% sensitivity to detect nodepositive disease, although infrarenal PALN was identified in only 1% compared to
inframesenteric PALN in 14% of all sentinel nodes [14].

Adjuvant therapy with combined modalities is commonly delivered in patients with
stage IIIC EC given the high local and distant recurrence rates in this group. The treatment
volume for adjuvant RT in women with FIGO stage IIIC1 is usually the vaginal cuff and pelvic
lymphatics [15, 16]. Because recurrence in the paraortic regions can be common ranging from 7
– 20% in women with FIGO stage IIIC1 despite adjuvant multimodality treatment [13, 17], some
physicians are reflexively recommending prophylactic radiation treatment to the paraaortic

area in women with FIGO stage IIIC1. However, there is a lack of consensus on the indications of
prophylactic PALN radiation, extent of the radiation target volume and the appropriate RT dose.

Two small retrospective studies reported no significant improvement in survival
endpoints with prophylactic paraoortic lymphatic irradiation in women with FIGO stage IIIC1 EC
[18, 19]. While useful, these two studies were hampered with some study limitations such as
the inclusion of patients who received preoperative radiation treatment[19] and the lack of
adjuvant chemotherapy in many patients [18, 19].

Using a multi-institutional pooled database, the primary goal of this study is to evaluate
the role of prophylactic PALN RT on survival outcomes and recurrence patterns in patients with
FIGO stage IIIC1 EC treated with adjuvant chemotherapy and radiation treatment using robust
statistical analyses including propensity score matching.

Materials and Methods

Following approval of the Institutional Review Board, a multi-institutional pooled data
collection was conducted including 13 academic centers for women with FIGO stage IIIC1 EC
who underwent surgical staging between 1995 and 2019. All patients received multimodality
adjuvant therapies including chemotherapy and radiation therapy. Clinical, surgical and
pathologic data were retrospectively recorded. Ineligibility criteria were defined as absence of
nodal sampling, carcinosarcoma histology, receipt of neoadjuvant chemotherapy or RT, and

receipt of a single adjuvant modality (chemotherapy or radiotherapy). Patients with residual
nodal and/or vaginal disease were included.

All patients underwent total hysterectomy, salpingo-oophorectomy, and lymph node
assessment followed by adjuvant chemotherapy and radiotherapy. All patients had
pathologically confirmed pelvic nodal involvement (FIGO stage IIIC1) without any pathologic or
radiologic evidence of PALN involvement. In addition, patients treated with adjuvant BT only or
unknown external radiation fields were excluded. Chemoradiotherapy treatment approaches
included upfront chemotherapy followed by radiation (upfront chemo), concurrent
chemoradiation (EBRT) followed by chemotherapy (concurrent), systemic chemotherapy before
and after EBRT (sandwich) and upfront EBRT followed by chemotherapy (upfront RT). The
sequencing approach for chemoradiotherapy was at the discretion of the physician and in line
with each institution’s practice. The indication for combination of EBRT and BT was left at the
discretion of the treating radiation oncologist and was mainly used for patient with cervical
stromal invasion. Prophylactic para-aortic field was defined as per GOG-258 where the upper
border was at T11-T12 [7].

Statistical analysis:

A total of 378 patients were included in this study who fulfilled our inclusion and
exclusion criteria. For the study purpose, the cohort was then divided into two subgroups, a
group who received adjuvant radiation treatment to the vaginal cuff and pelvic lymphatics (286
patients) and a group who received the same RT treatment volume but with the addition of a
prophylactic paraaortic radiation field (92 patients).

Descriptive statistics were used to characterize the patient cohort in terms of
demographics, tumor and treatment characteristics. Chi-squared tests were performed to
assess associations. Overall survival (OS) was defined from the date of surgery to the date of
death from any cause. Recurrence-free survival (RFS) was defined from the date of surgery date
to the date of first recurrence or progression or last follow-up. Time to endpoints were
calculated by Kaplan-Meier method. Univariable and multivariable analysis were performed by
Cox proportional hazard models for RFS/OS. The variables that were significant (p<0.2) on
univariate analysis (UVA) were included in the multivariate analysis. In the presence of co-linear
variables, only one variable was included in the multivariate analysis. Covariates evaluated by
UVA were age, race, histology, tumor grade, FIGO 2018 stage, depth of myometrial invasion,
presence of 2 or more positive nodes, presence of adnexal and cervical involvement,
lymphovascular invasion (LVSI), type and sequencing of adjuvant chemoradiotherapy and
radiation field extent (pelvic vs. pelvic + prophylactic PALN RT). Recurrences were categorized
into 4 categories: vaginal recurrence only, pelvic +/- vaginal recurrences, PALN +/- pelvic
recurrences and distant recurrences +/- pelvic and PALN recurrences.

In addition, propensity score matching were used to estimate the effect of the radiation
field with the addition of prophylactic PALN RT on survival outcomes. It was conducted using
1:1 nearest neighbor propensity score matching without replacement. The propensity score
was estimated using logistic regression of the radiation field on the covariates that may have
impact on survival outcomes, or on the selection of radiation fields, or on both. After matching,
all the covariates had a standardized mean difference below 0.1 except one (myometrial
invasion, 0.13), as shown in Figure 1, indicating adequate balance. We fit Cox regression models
to estimate the effect of the radiation field on survival outcomes with the matched data. Its
standard error was estimated using a cluster-robust variance with matching stratum
membership as the clustering variable. The p-value resulted from using the robust standard
error. Statistical analyses were conducted using SPSS version 27 and R version 4.0.2
(https://www.r-project.org/).

Results

Patient characteristics

A total of 378 patients with stage IIIC1 EC met the eligibility criteria and were included in
the analysis. The baseline clinical and pathologic characteristics for the entire cohort and the
risk factors distribution among the 2 treatments groups (pelvic RT vs. pelvic + prophylactic PALN
RT fields) are presented in Table 1. The median age at diagnosis was 62 (interquartile range
(IQR), 55 - 69 years). A majority of patients had endometrioid adenocarcinoma (72%), deep
myometrial invasion (greater than 50%) (71%), and presence of LVSI (79%). There were almost

as many patients with Grade 3 tumor (48%) as Grade 1 and 2 combined (52%). Adnexal and
cervical involvement were present in 62 (17%) and 135 (36%) of patients, respectively. Pelvic
and PALN assessment was performed in 171 patients (45%) while 207 patients (55%) had pelvic
lymph node dissection only. The median number of resected lymph nodes in the entire cohort
was 14 (IQR 9-21). The median number of resected lymph nodes in the pelvic RT group and
pelvic + PALN group was 15 (IQR 10-22) and 12 (IQR 8-17), respectively. The median number of
positive pelvic lymph nodes was 2 (IQR 1-2). A total of 17 patients had gross residual disease, 15
patients (4%) had nodal disease defined as R1 resection while 2 patients had vaginal and nodal
disease (0.5%). Chemoradiation sequencing for these patients was the following: 5 patients
received sequential chemoRT, 5 patients concurrent chemoRT and 7 patients received sandwich
chemoRT. Pelvic RT only was delivered to 9 patients while 8 patients received prophylactic
PALN RT. Most patients were treated with EBRT and brachy (71%). The median dose of EBRT
delivered was 46 Gy (IQR 45-53.5 Gy). Standard radiation doses (45-50.4 Gy) were delivered to
11 patients, 5 patients received EBRT nodal boost up to 55 Gy and 1 patient with both vaginal
and nodal residual disease received EBRT nodal boost and brachytherapy.

When comparing risk factors distribution among patients treated with pelvic RT and those
treated with prophylactic PALN RT field, no differences were seen for age, race, LVSI, depth of
myometrial invasion, cervical and adnexal involvement, and number of positive nodes (Table 1).
However, patients treated with prophylactic PALN RT field were more likely to have
endometrioid histology (p=0.02) and lower grade (p=0.01). As for the type of radiotherapy and
chemoradiotherapy sequencing, patients treated with prophylactic PALN RT field were more

likely to receive EBRT + BT and sequential chemoradiotherapy compared to those treated with
pelvic RT (p<0.001).

Treatment characteristics

Adjuvant chemotherapy agents included carboplatin, paclitaxel, taxotere, adriamycin and
cyclophosphamide, with carboplatin-paclitaxel being the most common regimen. Of the 378
patients, 178 (47%) received upfront chemotherapy, 75 (20%) received concurrent, 106 (28%)
received “sandwich”, and 19 (5%) received upfront RT.

The most commonly used chemotherapy regimen was carboplatin (Area Under the Curve=6)
and paclitaxel (175 mg/m2) every 3 weeks (90%). The median number of chemotherapy cycles
was 6 (IQR 4-6). Cisplatin was the most common agent used in the concurrent setting. A total of
75 patients were treated with concurrent chemoradiation of which most patients (79%)
received a total of 2 cycles of cisplatin while 17% of patients received cisplatin weekly followed
by a median of 4 (IQR4-6) adjuvant chemotherapy cycles.

Adjuvant radiotherapy was delivered using EBRT with or without BT. Among the entire
patient cohort, 120 (32%) received EBRT alone while 258 (68%) received EBRT and BT. The
median EBRT dose was 45Gy (range 41.4-58Gy) delivered in 25 (range 23-31) fractions. The
median dose of intracavitary BT was 12 Gy (range 5-25 Gy) in 2 (range 1-6) fractions. A majority
of patients were treated with pelvic RT (n=286, 76%) while a smaller number of patients were
treated with prophylactic PALN RT field (n=92, 24%).

Treatment outcomes and prognostic factors

The median follow-up was 45.8 months (IQR, 23 – 74 months) for the entire cohort. The
estimated overall survival and recurrence-free survival rates at 5 years were 80% and 69%,
respectively, for the entire cohort. There was no difference in the 5-year OS (77% vs. 87%,
p=0.47) and RFS rates (67% vs. 70%, p=0.78) between patients treated with pelvic RT and those
with prophylactic PA RT field, respectively as shown in Figure 2A and 2B. Among patients with
endometrioid histology, there was no difference in the 5-year OS (86% vs. 88%, p=0.7) and RFS
rates (74.5%

vs. 77%, p=0.9) between patients treated with pelvic RT and those with

prophylactic PALN RT field, respectively. Similarly among patients with non-endometrioid
histology, there was no difference in the 5-year OS (60% vs. 70%, p=0.4) and RFS rates (51% vs.
31%, p=0.45).

When comparing 171 patients (45%) with PALN sampling and 207 patients (55%) with only
pelvic lymph node dissection, women who had PALN sampling were more likely to get pelvic RT
(82.5%) compared to those who did not have PALN sampling (70%), p=0.005. However, PALN
sampling was not associated with OS or RFS (p > 0.05). In subgroup analysis of patients without
PALN sampling, there was no difference in the 5-year OS (80% vs. 82%, p=0.63) between
patients treated with pelvic RT and those treated with prophylactic PA RT field (Table 3). On
univariate analysis for OS, age, race, depth of myometrial invasion, LVSI, number of positive
pelvic nodes, type of radiation delivered (EBRT vs EBRT + BT) and chemoradiotherapy
sequencing approach were not associated with overall survival (p≥0.05). Non-endometrioid
histology (p<0.001), grade 3 (p<0.001), presence of adnexal (p=0.001) and cervical involvement

(p=0.008) were associated with worse OS. As for the extent of radiation field, no difference in
OS was seen between patients treated with prophylactic PALN RT field vs. pelvic (p=0.50) (Table
4). On multivariate analysis, grade 3 (p = <0.001) and presence of adnexal involvement (p =
0.003) were significantly associated with worse OS (Table 5).

On univariate analysis for RFS, race (p=0.06), the number of positive pelvic lymph nodes
(p=0.26), type of radiation delivered (EBRT vs EBRT +BT) (p=0.83) and chemoradiotherapy
sequencing approaches (p=0.24) were not associated with RFS. Age ≥60 (p=0.02), nonendometrioid histology (p<0.001), grade 3 (p<0.001), myometrial invasion >50% (p=0.03),
presence of LVSI (p=0.01), adnexal (p=0.001) and cervical involvement (p=0.001) were
significantly associated with worse RFS. The extent of radiation field was not associated with
RFS (p=0.78) (Table 4). On multivariate analysis, grade 3 (p < 0.001) and presence of adnexal
involvement (p=0.007) were significantly associated with worse RFS (Table 5).

After propensity score matching, the estimated Hazard Ratios (HR) of prophylactic PALN RT
field vs. pelvic RT field were 1.50 (95% CI = (0.71, 3.19), p-value = 0.28) for OS and 1.24 (95% CI
= (0.64, 2.42), p-value = 0.51) for RFS, indicating that there was not enough evidence showing
prophylactic PALN RT field associated with improved survival outcomes (Figure 2C, 2D).

Patterns of failure

A total of 100 (26%) patients had disease recurrence, among which 75 had received
pelvic RT and 25 had received prophylactic PALN RT field. Distant recurrence was the most

common site of first recurrence (18.1% vs. 18.5%), followed by PALN (4.5% vs. 3.3%), pelvic LN
only (1.4% vs. 3.3%), vagina only (1.4% vs. 1.1%) and pelvic LN with vagina (0.7% vs. 1.1%) in
patients who received pelvic RT and those who received prophylactic PALN RT field,
respectively (Table 6). EBRT field was not associated with the site of first recurrence (P=0.79). A
total of 16 patients (4.2%) had isolated para-aortic relapses, among which 13 had received
pelvic RT and 3 had received prophylactic PALN RT field. Among these 16 isolated PALN
recurrences, 11 patients (69%) had age > 60 years, 11 (69%) endometrioid histology, 11 (69%)
grade 3 tumor, 13 (81%) deep myometrial invasion, 15 (94.8%) presence of LVSI, 3 (19%)
adnexal involvement, 7 (44%) cervical involvement, 12 (75%) EBRT + BT, 13 (81%) pelvic RT, 8
(50%) upfront chemotherapy and 6 (37.5%) “sandwich” chemotherapy.

Discussion

After extensive literature search, we believe that this is the largest study to evaluate the
role of prophylactic PALN irradiation in women with stage IIIC1 EC who were treated with
combined modality therapy including chemotherapy and radiation therapy. In our study and in
agreement with other investigators [18, 19], prophylactic PALN RT did not statistically improve
recurrence-free and overall survival in women with stage IIIC1 endometrial carcinoma who
received adjuvant chemotherapy and RT.

In our study only 45% of patients had PALN sampling while 55% had only pelvic lymph
node dissection, reflecting the lack of strong guidelines for PALN assessment. PALN sampling
was recommended for macroscopic positive pelvic nodes or para-aortic nodes, or both as per

PORTEC 3, while pelvic lymph node sampling and para-aortic lymph node sampling were left
optional as per GOG 258 [5-7]. The results of our study reflect the current practice across the
United States and Canada, where PALN sampling is not systematically performed and
prophylactic PALN RT is delivered at the discretion of the treating radiation oncologist. PALN
irradiation was likely deemed unnecessary in patients who had negative PALN sampling,
reflected by higher proportion of women with PALN sampling treated with pelvic RT (82.5%)
compared to those without PALN sampling (70%). However, neither PALN sampling nor extent
of radiation field was associated with OS or RFS.

On multivariate analysis, tumor grade and adnexal involvement were the only significant
predictors of OS and RFS. Histology was not a significant predictor of OS and RFS on
multivariate analysis, as detecting statistical significance is challenging given that an
overwhelming majority of histology consisted of endometrioid (72.2%) vs. non-endometrioid
(27.8%) in this study. Distant recurrence remains the most common site of first recurrence both
in patients treated with pelvic RT and prophylactic PALN RT field. The patterns of failure were
not correlated with the radiation treatment fields or chemoradiotherapy sequencing
approaches.

Based on randomized trials including phase 3 trials demonstrating survival benefit with
systemic chemotherapy [5-7, 20, 21], combined chemotherapy and radiotherapy forms the
established framework of adjuvant therapy in the current treatment guidelines [15, 16, 22].
While the use of adjuvant chemoradiation has become a routine practice, there is a lack of
consensus regarding the details on radiation target volume, and therefore the ideal RT target

remains controversial especially in the setting of positive pelvic lymph node EC without PALN
involvement. This study evaluates the role of prophylactic PALN radiation therapy in stage IIIC1
EC. The 5-year overall survival and recurrence-free survival for stage IIIC disease varies between
60-90% and 59-80%, respectively [5, 7, 20, 21, 23-26]. Differences in survival outcomes across
the studies are mainly due to variations in patient selection and treatment modalities.
Meanwhile, there are fewer studies reporting survival outcomes of stage IIIC1 specifically, and
these retrospective studies reported 5-year survival estimates as high as 85.7% [23] and as low
as 23% for IIIC1 disease with multitude of comorbidities [27].

The large randomized phase III PORTEC-3 trial included 686 high-risk EC patients and
reported 5-year OS of 78.7% and failure-free survival of 69.3% in subgroup analysis of stage III
patients [5]. The 5-year OS of 80% and RFS of 69% in our study are very comparable to the
survival outcomes of PORTEC-3 trial [5]. Another large randomized phase III GOG 258 trial
reported a lower 5-year relapse-free survival of 59% possibly due to inclusion of larger
proportion of stage IIIC patients who may have an inherently higher risk of local relapse
compared to other high-risk stage I-II patients [7]. While the historical Surveillance,
Epidemiology, and End Results (SEER) analysis using the database from 1988 to 2001 showed 60%
survival rate among women with stage III EC (2009 FIGO staging) [25], the updated analysis
using the more recent SEER database from 2004 to 2012 reported the 3-year OS of 80.5% [26],
which again is very comparable to the 5-year OS of 80% in our study. The steep rise of the
survival outcomes observed in the more recent analysis may be due to improved treatment
modalities including introduction of chemotherapy and advancement of radiation techniques.

The standard extended-field radiotherapy is defined as the pelvic volume plus the entire
common iliac chain and PALN region [22]. Although studies have shown the benefit of
extended-field radiotherapy in decreasing PALN failure [28, 29] and improving overall survival
and distant metastasis [30] in the setting of cervical cancer, the benefit appears less robust for
endometrial carcinoma. On one hand, the National Comprehensive Cancer Network guidelines
recommend the upper border of the extended field cover at least 1-2 cm above the level of the
renal vessels, though it suggests that the ultimate RT volume be determined at the discretion of
the treating physician depending on the clinical situation [22]. On the other hand, the RTOG
2021 consensus guidelines recommends coverage of the PALN chain when there is pathologic
or radiographic evidence of PALN involvement or substantial risk of microscopic disease is
suspected by the clinician with moderate agreement for para-aortic nodal CTV with the upper
border covering 1 to 1.5 cm above the left renal vessels [31]. In summary, data on the volume
of prophylactic PALN RT field may vary without substantial agreement for para-aortic nodal
volume by experts [22, 31]. Furthermore, prophylactic PALN RT field is known to be associated
with higher toxicities, especially acute gastrointestinal and hematologic toxicities [32], hence it
is not routinely delivered in the prophylactic setting. Therefore, institutional variations and
clinician preferences ultimately dictate the radiation treatment fields.

To our knowledge, there is no prospective data and few retrospective studies comparing
the treatment fields for clinical outcomes in patients with stage IIIC1 disease. Our study did not
report a correlation between treatment field extent and survival outcomes. Patterns of failure
were similar for pelvic and prophylactic PALN RT field, and distant metastases remains the

dominant pattern of first recurrence. Similarly, Onal et al. reported no significant difference
between pelvic RT and prophylactic PALN RT field in terms of overall survival, progression-free
survival and patterns of failure in a cohort of 167 women with stage IIIC1 disease who were
treated with either adjuvant RT to the pelvis (64%) or to the pelvis and PALN (36%) with or
without systemic chemotherapy [18]. The latter study also showed that patients who received
pelvic RT with chemotherapy had better OS and PFS compared to those who received pelvic
and prophylactic extended PALN field without chemotherapy and concluded that prophylactic
PALN RT field is unnecessary, even if chemotherapy is used together with pelvic-RT [18].
However, our study differed from that of Onal et al. in that all patients in our study cohort
received adjuvant chemotherapy. While 80% of patients received adjuvant chemotherapy in
Onal’s study cohort, the proportion of patients receiving chemotherapy was significantly higher
among patients treated with pelvic RT compared to those treated with prophylactic PALN RT
field (67% vs. 33%, p = 0.05) [18]. Propensity matching was performed in both our study and
Onal study, and subgroup analysis of matched cohort in Onal study showed no difference in the
5-year OS and RFS between pelvic RT and prophylactic PALN RT in patients treated with or
without chemotherapy [18].

A similar study by Holloway et al. reported a higher 5-year OS in patients treated with
prophylactic PALN RT field compared to pelvic RT (79.1% vs. 47.0%, P=0.01) among 57 women
with EC with N1-only involvement who were treated with either adjuvant pelvic RT (40%) or
prophylactic PALN RT field (60%) [19]. On multivariate analysis, however, radiation therapy
volume was not significantly associated with survival [19]. In addition, despite the observed

trend for lower recurrence rates in those who received prophylactic PALN RT field (26 % vs. 52%,
P=0.06), the vast majority of first recurrences occurred at distant sites in both groups, and there
were no isolated PALN recurrences even among those who did not receive prophylactic PALN
RT field [19]. Similarly, in our study, distant recurrence was the most common site of first
recurrence both in patients treated with pelvic RT and prophylactic PALN RT field, followed by
PALN with or without pelvis, pelvis only, vagina only, and pelvis with vagina. The patterns of
failure found by Holloway et al. and our study are consistent with the results of other studies
prospective and randomized that found that the majority of recurrences in women with stage
IIIC endometrial cancer typically occur at distant sites [6, 7, 24, 33, 34].

In contrast to these findings, Lee et al. reported that the most common site of
recurrence in patients treated with pelvic RT was the para-aortic chain (12%) followed by
distant recurrence and pelvis, while the most common site of recurrence in patients treated
with prophylactic PALN RT field was distant recurrence followed by para-aortic chain and pelvis
[35]. The latter study has several limitations including the small number of patients in this
subset and the failure to detect if chemotherapy reduced the risk of PALN failure when pelvic
RT was delivered [35]. Furthermore, only 67% of patients received adjuvant chemotherapy and
the proportion of patients receiving chemotherapy in respective radiation fields – pelvic RT,
prophylactic PA RT field, and whole-abdominal RT - was unknown in Lee’s study [35]. Unlike
these prior studies that included patients who received various types of adjuvant therapy [18,
19, 35], our study is unique in examining only patients treated with combined adjuvant

chemoradiation therapy such that the presence or absence of chemotherapy is not a
confounding factor.

We acknowledge that our study has several limitations. First, it is a retrospective study
with inherent selection and information biases. A small proportion of patients was treated with
prophylactic PALN RT field which reflects the current practice and lack of consensus on the
extent of radiation fields for locally advanced EC with positive pelvic nodes. While most
variables were balanced between the 2 treatment groups, there were significantly more
favorable grade and histology in the PALN RT group. Treatment-related toxicities were not
reported due to the limited data available and the grading heterogeneity across the 13
participating centers. Prophylactic PALN RT field is known to be associated with higher toxicities
mainly gastrointestinal and hematologic [32, 36], which is the major drawback of its routine use.
Assessment of acute and chronic toxicities may have served as valuable information to further
evaluate the risks and benefits of the prophylactic PALN RT field. Furthermore, the sequencing
of chemotherapy also varied including upfront chemo, concurrent and “sandwich” regimen,
and upfront RT. In our previous publication, sequencing approaches of chemoradiotherapy did
not impact survival outcomes [37]. Despite these limitations, our study provides valuable
outcomes data on the effects of prophylactic PALN RT in patients with nodal involvement
limited to the pelvis. In the few studies that stratified the results in stage IIIC1 vs. IIIC2, the
results are based on smaller patient sample sizes (n<60) [17, 19, 23, 38], illustrating the value of
our large study that consists of 378 stage IIIC1 patients. To our knowledge, our study is the
largest retrospective series available at this time that evaluates the role of radiation treatment

volume on the clinical outcomes and the patterns of failure among patients with stage IIIC1
endometrial carcinoma which could impact clinical practice by helping clinicians in decisionmaking.

Conclusion

In this multi-institutional analysis of women with stage IIIC1 endometrial cancer,
prophylactic PALN RT field was not significantly associated with improved survival outcomes.
Distant recurrence was the most common site of failure both in patients treated with pelvic RT
and prophylactic PALN RT field. This study suggests that prophylactic PALN RT field is not
warranted in the setting of pelvic lymph node positive EC without PALN involvement. As distant
metastasis remains the most site of failure despite routine use of systemic chemotherapy, new
therapeutic approaches including molecular markers are necessary to optimize the outcomes
for women with stage IIIC1 endometrial cancer.
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Figure 1. The Kaplan-Meier estimate curves for (A) OS and (B) RFS for Pelvic RT and prophylactic
PALN RT in the entire cohort. The (C) OS and (D) RFS for pelvic RT and prophylactic PALN
RT field in the matched cohort.
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Table 1. Patient characteristics and risk factors according to the extent of the radiation field in the entire cohort
Pelvic +
Entire cohort n=378
Pelvic RT, n=286
prophylactic PA
Characteristics
(%)
(%)
field RT, n=92 (%)
P-value
Median age (years)

62 (IQR 55-69)

62 (IQR 55-70)

62 (IQR 54-67)

< 60

165 (44%)

121 (42%)

44 (48%)

≥ 60

213 (56%)

165 (58%)

48 (52%)

Median number of pelvic LN +

2 (IQR 1-2)

2 (IQR 1-2)

2 (IQR 1-2)

Median number of LN resected

14 (IQR 9-21)

15 (IQR 10-22)

12 (IQR 8-17)

1

186 (49%)

146 (51%)

40 (43%)

≥2

192 (52%)

140 (49%)

52 (57%)

Endometrioid

273 (72%)

197 (69%)

76 (83%)

Non-endometrioid

105 (28%)

89 (31%)

16 (17%)

I and II

196 (52%)

137 (48%)

59 (65%)

III

179 (48%)

147 (52%)

32 (35%)

< 50%

109 (29%)

82 (29%)

27 (29%)

≥ 50%

269 (71%)

204 (71%)

65 (71%)

Absent

306 (83%)

237 (84%)

69 (80%)

Present

62 (17%)

45 (16%)

17 (20%)

Absent

238 (64%)

177 (62%)

61 (68%)

Present

135 (36%)

107 (38%)

28 (32%)

Non-black

321 (88%)

240 (88%)

81 (90%)

Black

43 (12%)

34 (12%)

9 (10%)

Absent

79 (21%)

61 (22%)

18 (20%)

Present

292 (79%)

220 (78%)

72 (80%)

Age
0.42

Positive LN
0.25

Pathology
0.02

Grade
0.01

Depth of myometrial invasion
1.00

Adnexal involvement
0.51

Cervical involvement
0.35

Race
0.67

LVSI
0.84

Type of RT
EBRT alone

120 (32%)

106 (37%)

14 (15%)

EBRT + BT

258 (68%)

180 (63%)

78 (85%)

< .001

Treatment sequencing
Upfront CHT

178 (47%)

117 (41%)

61 (66%)

Concurrent CHT

75 (20%)

60 (21%)

15 (16%)

“Sandwich” method

106 (28%)

96 (34%)

10 (11%)

Upfront RT

19 (5%)

13 (4%)

6 (7%)

< .001

LN: lymph node; IQR: interquartile range; LVSI: lymphovascular space invasion; PA: para-aortic; RT: radiotherapy; EBRT: external
beam radiotherapy; CHT: chemotherapy; “Sandwich” method: initial chemotherapy of limited duration, followed by
radiotherapy, and then subsequent consolidation chemotherapy again.

Table 2. Patient characteristics and risk factors according to the extent of the radiation field in the matched cohort
Pelvic +
Entire cohort n=166
prophylactic PA
Characteristics
(%)
Pelvic RT, n=83 (%)
field RT, n=83 (%)
P-value
Median age (years)

61 (IQR 54-68)

61 (IQR 54-68)

61 (IQR 54-67)

< 60

78 (47%)

38 (46%)

40 (48%)

≥ 60

88 (53%)

45 (54%)

43 (52%)

2 (IQR 1-3)

2 (IQR 1-3)

2 (IQR 1-3)

1

77 (46%)

39 (47%)

38 (46%)

≥2

89 (54%)

44 (53%)

45 (54%)

Endometrioid

140 (84%)

71 (86%)

69 (83%)

Non-endometrioid

26 (16%)

12 (15%)

14 (17%)

I and II

101 (61%)

48 (58%)

53 (65%)

III

64 (39%)

35 (42%)

29 (35%)

< 50%

57 (34%)

31 (37%)

26 (31%)

≥ 50%

109 (66%)

52 (63%)

57 (69%)

Absent

135 (81%)

68 (82%)

67 (81%)

Present

31 (19%)

15 (18%)

16 (19%)

Absent

116 (70%)

57 (69%)

59 (71%)

Present

50 (30%)

26 (31%)

24 (29%)

Non-black

150 (90%)

76 (92%)

74 (89%)

Black

16 (10%)

7 (8%)

9 (11%)

Absent

34 (21%)

16 (19%)

18 (22%)

Present

132 (79%)

67 (81%)

65 (78%)

Age

Median number of pelvic LN +

0.88

Positive LN
1.00

Pathology
0.83

Grade
0.46

Depth of myometrial invasion
0.51

Adnexal involvement
1.00

Cervical involvement
0.87

Race
0.79

LVSI
0.85

Type of RT
EBRT alone

22 (13%)

11 (13%)

11 (13%)

EBRT + BT

144 (87%)

72 (87%)

72 (87%)

1.00

Treatment sequencing
Upfront CHT

118 (71%)

60 (72%)

58 (70%)

Concurrent CHT

22 (13%)

10 (12%)

12 (14%)

“Sandwich” method

17 (10%)

9 (11%)

8 (10%)

Upfront RT

9 (5%)

4 (5%)

5 (6%)

0.94

LN: lymph node; IQR: interquartile range; LVSI: lymphovascular space invasion; PA: para-aortic; RT: radiotherapy; EBRT: external
beam radiotherapy; CHT: chemotherapy; “Sandwich” method: initial chemotherapy of limited duration, followed by
radiotherapy, and then subsequent consolidation chemotherapy again.

Table 3: Extent of radiation field by para-aortic lymph node sampling

No PALN Sampling (n=206)
PALN Sampling (n=171)
Total (n=377)

Pelvic RT
144 (70%)
141 (83%)
285 (76%)

PA: para-aortic; PALN: para-aortic lymph node; RT: radiotherapy

Prophylactic PA
RT
62 (30%)
30 (17%)
92 (24%)

Table 4. Univariate analysis of prognostic factors for overall survival and recurrence-free
survival
Variables

HR (95% CI)

P-value

Overall survival
Age ≥ 60 vs. < 60

1.42 (0.88-2.27)

0.15

Race black vs. other

1.83 (0.98-3.40)

0.06

Myometrial invasion ≥ 50% vs. < 50%

1.76 (0.98-3.16)

0.06

LVSI present vs. absent

1.86 (0.92-3.74)

0.08

Number of pelvic LN+ ≥ 2 vs. 1

1.60 (1.00-2.55)

0.05

Type of RT EBRT vs. EBRT + BT

0.94 (0.57-1.55)

0.80

Treatment sequencing

0.54

Upfront chemo vs. concurrent

1.24 (0.64-2.42)

Upfront chemo vs. sandwich

1.50 (0.87-2.61)

Upfront chemo vs. upfront RT

1.33 (0.56-3.18)

Histology non-endometrioid vs. endometrioid

2.59 (1.63-4.10)

<0.001

Grade 3 vs. 1-2

3.05 (1.85-5.03)

<0.001

Adnexal involvement present vs. absent

2.38 (1.45-3.88)

0.001

Cervical involvement present vs. absent

1.87 (1.18-2.98)

0.008

Field of RT PALN prophylactic vs. pelvic

0.83 (0.47-1.44)

0.50

1.64 (1.08-2.48)

0.02

Recurrence-free survival
Age ≥60 vs. <60

Race black vs. other

1.67 (0.98-2.87)

0.06

Myometrial invasion ≥ 50% vs. < 50%

1.72 (1.05-2.81)

0.03

LVSI present vs. absent

2.45 (1.27-4.73)

0.01

Number of pelvic LN+ ≥ 2 vs. 1

1.26 (0.85-1.88)

0.26

Type of RT EBRT vs. EBRT + BT

1.05 (0.68-1.63)

0.83

Treatment sequencing

0.24

Upfront chemo vs. concurrent

1.15 (0.66-2.03)

Upfront chemo vs. sandwich

1.63 (1.03-2.58)

Upfront chemo vs. upfront RT

1.31 (0.55-3.08)

Histology non- endometrioid vs endometrioid

2.28 (1.53-3.40)

<0.001

Grade 3 vs. 1-2

3.36 (2.18-5.20)

<0.001

Adnexal involvement present vs. absent

2.15 (1.39-3.33)

0.001

Cervical involvement present vs. absent

1.92 (1.28-2.87)

0.001

Field of RT PALN prophylactic vs. pelvic

0.94 (0.59-1.49)

0.78

LVSI: lymphovascular space invasion; LN: lymph node; PALN: para-aortic lymph
node; RT: radiotherapy; EBRT: external beam radiotherapy; BT: brachytherapy;
“Sandwich”: initial chemotherapy of limited duration, followed by radiotherapy,
and then subsequent consolidation chemotherapy again.

Table 5. Multivariate analysis of prognostic factors for overall survival and recurrence-free
survival
Variables
HR (95% CI)
P-value
Overall survival
Age ≥ 60 vs. < 60
1.50 (0.91-2.49)
0.11
Myometrial invasion ≥ 50% vs. < 50%
1.49 (0.82-2.70)
0.19
Positive LN ≥ 2 vs. 1
1.39 (0.86-2.27)
0.18
Grade 3 vs. 1-2
2.59 (1.54-4.36)
<0.001
Adnexal involvement present vs. absent
2.19 (1.30-3.69)
0.003
Cervical involvement present vs. absent
1.38 (0.84-2.27)
0.21
Recurrence-free survival
Age ≥ 60 vs. < 60
1.53 (0.99-2.36)
0.06
LVSI present vs. absent
2.04 (1.02-4.09)
0.05
Grade 3 vs. 1-2
3.00 (1.90-4.76)
<0.001
Adnexal involvement present vs. absent
1.87 (1.19-2.96)
0.007
LN: lymph node; LVSI: lymphovascular space invasion.

